Automation to support phase 1 solid tumour trial
Automation to support phase 1 solid tumour trial
New centre at health innovation hub boosts trial delivery
Consortium to advance EXO‑101 for osteoarthritis
UK authorisation and reimbursement extended to younger children
Viewpoint urges shift in antifibrotic trial endpoints
Automation to support phase 1 solid tumour trial
Progress builds momentum for targeted Hutchmed and AstraZeneca treatment
One‑year graft failure‑free survival reaches 90% in crossmatch‑positive transplants
Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease
SARON trial shows 56% improvement over standard treatment
MAD World Summit 2026 has secured official accreditation from The CPD Group
Early responses suggest restored sensitivity to anti‑PD‑1 therapy
First-in-class therapy offers functional cure potential
First SC option offers new flexibility for patients
Second-line authorisation expands immunotherapy options